Michael B. Atkins, MD, discusses the importance of the Georgetown Lombardi Cancer Center Consortium.
Michael B. Atkins, MD, deputy director of the Georgetown Lombardi Comprehensive Cancer Center, and the Scholl Professor and vice chair of the Department of Medical Oncology at Georgetown University Medical Center, discusses the importance of the Georgetown Lombardi Cancer Center Consortium.
A 19-year-old male with stage 4 epithelioid sarcoma who progressed on multiple prior lines of therapy, including EZH2 inhibitors, enrolled on the Georgetown Lombardi Cancer Center Consortium, explains Atkins.
After careful consideration, and all other treatment options had been exhausted, Andrew L. Pecora, MD, of John Theurer Cancer Center at Hackensack Meridian Health, administered the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) to the patient, Atkins says. Although this combination has received FDA approval in several other indications, it had not previously been explored in this rare sarcoma subtype.
In 2 weeks, the patient achieved a complete remission and was able to resume normal daily activity, concludes Atkins.